hydralazine has been researched along with Breast Cancer in 8 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance." | 7.85 | Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. ( Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A, 2017) |
| "To detect the 5'CpG island methylation of estrogen receptor (ER) alpha gene promotor region in ER alpha-negative human breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and breast cancer tissues; and to investigate the possibility of hydralazine in restoring the expression of ER alpha gene through demethylation." | 7.73 | [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation]. ( Jiang, J; Tang, B, 2005) |
| " As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine, plus the HDAC inhibitor magnesium valproate, were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy." | 5.12 | A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. ( Arce, C; Bargallo, E; Camargo, MF; Candelaria, M; Chávez-Blanco, A; de la Cruz-Hernández, E; Dueñas-González, A; González-Fierro, A; Pérez-Cárdenas, E; Pérez-Plasencia, C; Ramírez, T; Revilla-Vázquez, A; Robles, E; Taja-Chayeb, L; Trejo-Becerril, C; Vela, T; Villarreal, P, 2006) |
| "We describe a novel ER+ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance." | 3.85 | Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. ( Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A, 2017) |
| "To detect the 5'CpG island methylation of estrogen receptor (ER) alpha gene promotor region in ER alpha-negative human breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and breast cancer tissues; and to investigate the possibility of hydralazine in restoring the expression of ER alpha gene through demethylation." | 3.73 | [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation]. ( Jiang, J; Tang, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hilakivi-Clarke, L | 1 |
| Wärri, A | 1 |
| Bouker, KB | 1 |
| Zhang, X | 1 |
| Cook, KL | 1 |
| Jin, L | 1 |
| Zwart, A | 1 |
| Nguyen, N | 1 |
| Hu, R | 1 |
| Cruz, MI | 1 |
| de Assis, S | 1 |
| Wang, X | 1 |
| Xuan, J | 1 |
| Wang, Y | 1 |
| Wehrenberg, B | 1 |
| Clarke, R | 1 |
| Jiang, Y | 1 |
| Huang, Y | 1 |
| Cheng, C | 1 |
| Lu, W | 1 |
| Zhang, Y | 1 |
| Liu, X | 1 |
| Zou, L | 1 |
| Ben, Q | 1 |
| Shen, A | 1 |
| Segura-Pacheco, B | 1 |
| Trejo-Becerril, C | 2 |
| Perez-Cardenas, E | 2 |
| Taja-Chayeb, L | 2 |
| Mariscal, I | 1 |
| Chavez, A | 1 |
| Acuña, C | 1 |
| Salazar, AM | 1 |
| Lizano, M | 1 |
| Dueñas-Gonzalez, A | 2 |
| PERRY, HM | 1 |
| Knowles, HJ | 1 |
| Tian, YM | 1 |
| Mole, DR | 1 |
| Harris, AL | 1 |
| Tang, B | 1 |
| Jiang, J | 1 |
| Arce, C | 1 |
| Pérez-Plasencia, C | 1 |
| González-Fierro, A | 1 |
| de la Cruz-Hernández, E | 1 |
| Revilla-Vázquez, A | 1 |
| Chávez-Blanco, A | 1 |
| Bargallo, E | 1 |
| Villarreal, P | 1 |
| Ramírez, T | 1 |
| Vela, T | 1 |
| Candelaria, M | 1 |
| Camargo, MF | 1 |
| Robles, E | 1 |
| Kaufman, DW | 1 |
| Kelly, JP | 1 |
| Rosenberg, L | 1 |
| Stolley, PD | 1 |
| Schottenfeld, D | 1 |
| Shapiro, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma[NCT00395655] | Phase 2 | 43 participants | Interventional | 2005-06-30 | Terminated | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydralazine and Breast Cancer
| Article | Year |
|---|---|
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA | 2006 |
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA | 2006 |
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA | 2006 |
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA | 2006 |
7 other studies available for hydralazine and Breast Cancer
| Article | Year |
|---|---|
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenovirus E1A Proteins; Animals; Antineoplastic Combined Chemothe | 2017 |
Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Female | 2011 |
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Cycle; Cyclin-Dependen | 2003 |
CARCINOMA AND HYDRALAZINE TOXICITY IN PATIENTS WITH MALIGNANT HYPERTENSION.
Topics: Breast Neoplasms; Carcinoma; Humans; Hydralazine; Hypertension; Hypertension, Malignant; Lung Neopla | 1963 |
Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
Topics: Adrenomedullin; Angiogenesis Inducing Agents; Animals; Breast Neoplasms; Carcinoma; Carcinoma, Renal | 2004 |
[Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; CpG Islands; DNA Methyla | 2005 |
Hydralazine and breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Hydralazine; Middle Aged; Time Factors | 1987 |